Immunovant, Inc. (IMVT)
32.15
+0.04
(+0.12%)
USD |
NASDAQ |
Oct 07, 14:30
Immunovant Enterprise Value : 5.825B for Oct. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 06, 2026 | 5.825B |
| October 05, 2026 | 6.061B |
| October 02, 2026 | 6.137B |
| October 01, 2026 | 6.143B |
| September 30, 2026 | 6.170B |
| September 29, 2026 | 6.104B |
| September 28, 2026 | 6.110B |
| September 25, 2026 | 6.071B |
| September 24, 2026 | 6.215B |
| September 23, 2026 | 6.327B |
| September 22, 2026 | 6.894B |
| September 21, 2026 | 6.871B |
| September 18, 2026 | 6.824B |
| September 17, 2026 | 6.968B |
| September 16, 2026 | 6.706B |
| September 15, 2026 | 6.762B |
| September 14, 2026 | 6.970B |
| September 11, 2026 | 6.908B |
| September 10, 2026 | 7.061B |
| September 09, 2026 | 7.195B |
| September 08, 2026 | 7.364B |
| September 04, 2026 | 7.298B |
| September 03, 2026 | 7.271B |
| September 02, 2026 | 7.348B |
| September 01, 2026 | 7.432B |
| Date | Value |
|---|---|
| August 31, 2026 | 7.622B |
| August 28, 2026 | 7.700B |
| August 27, 2026 | 8.241B |
| August 26, 2026 | 8.255B |
| August 25, 2026 | 8.175B |
| August 24, 2026 | 8.138B |
| August 21, 2026 | 8.354B |
| August 20, 2026 | 8.350B |
| August 19, 2026 | 8.476B |
| August 18, 2026 | 8.340B |
| August 17, 2026 | 8.218B |
| August 14, 2026 | 7.828B |
| August 13, 2026 | 7.828B |
| August 12, 2026 | 7.989B |
| August 11, 2026 | 7.645B |
| August 10, 2026 | 7.430B |
| August 07, 2026 | 7.442B |
| August 06, 2026 | 7.399B |
| August 05, 2026 | 7.304B |
| August 04, 2026 | 7.321B |
| August 03, 2026 | 7.145B |
| July 31, 2026 | 7.168B |
| July 30, 2026 | 7.346B |
| July 29, 2026 | 7.166B |
| July 28, 2026 | 7.226B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Roivant Sciences Ltd. | 22.63B |
| Moderna, Inc. | 70.95B |
| Altimmune, Inc. | 228.94M |
| Vertex Pharmaceuticals, Inc. | 121.37B |
| First Tracks Biotherapeutics, Inc. | 947.23M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -153.22M |
| Total Expenses (Quarterly) | 153.22M |
| EPS Diluted (Quarterly) | -0.7454 |
| Earnings Yield | -8.74% |
| Normalized Earnings Yield | -8.738 |